ASBP

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place June 24th & 25th, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here. "This week's Life Sciences Virtual Investor Forum brings

8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)

ESTERO, Fla., June 17, 2026 (GLOBE NEWSWIRE) -- Aspire Biopharma Holdings, Inc.'s (NASDAQ:ASBP) ("Aspire" or the "Company"), today announced that it will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on June 25th, 2026. DATE: June 25th   TIME: 2:00 pm ET REGISTER HERE Available for 1x1 meetings: June 24-25. Schedule 1x1 Meetings here. The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportunity to submit questions to management in real time. A replay of the webcast will be available following the conclusion of the conference. It is recommend

8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)

8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)

Adds an established global brand with scale in large and growing markets driven by trends in vehicle and mobility control systemsAcquisition significantly accelerates Aspire's revenue, earnings growth and cash flow profileStrategically diversifies Aspire's revenue streamsOpportunity to drive significant shareholder value creation and enhance long-term capital allocation optionalityCompany does not anticipate procuring new equity financing to consummate the transaction ESTERO, FL / ACCESS Newswire / June 12, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), today announced the signing of a definitive Share Purchase Agreement ("SPA") for the acquisition of 100%

ESTERO, FL / ACCESS Newswire / May 28, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today issued the following letter to shareholders from Chief Executive Officer Kraig Higginson.Dear Fellow Shareholders,2026 is shaping up to be a defining year for Aspire Biopharma Holdings. We are moving with speed to transform our clinical pipeline into commercial reality, broadening the market reach of our high growth consumer segment, while simultaneously diversifying our business through a proposed strategic acquisition.Capital Market MilestonesOur Board of Directors recentl

ESTERO, FL / ACCESS Newswire / May 27, 2026 / Aspire Biopharma Holdings, Inc.'s (NASDAQ:ASBP) ("Aspire" or the "Company") wholly owned subsidiary Buzz Bomb Caffeine Company LC is proud to announce a strategic partnership with EoS Fitness, the High Value. Low Price.® (HVLP) gym chain with more than 225 locations open or on the way nationwide. Through the EoS Flex Deals affiliate program, BUZZ BOMB™ 's lineup of 50mg sublingual caffeine stick packs will now be available to an expansive community of health-conscious gym members. The EoS Flex Deals affiliate program is a premier partnerships platform designed to connect members with brands aligned with the EoS mission. With over 80 million impr

10-Q - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)

SCHEDULE 13G - Aspire Biopharma Holdings, Inc. (0001847345) (Subject)

8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)

SCHEDULE 13G/A - Aspire Biopharma Holdings, Inc. (0001847345) (Subject)

DEFR14A - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)

DEF 14A - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)

ESTERO, FL / ACCESS Newswire / May 7, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that it will effect a one-for-thirty (1:30) reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on May 11, 2026, at 12:01 AM Eastern Time, before the opening of trading on The Nasdaq Capital Market ("Nasdaq"). Aspire has requested that its Common Stock begin trading on May 11, 2026, on a post-reverse split basis on the Nasdaq under the existing symbol "ASBP".The reverse split is primarily intended to

PRE 14A - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)

ESTERO, FL / ACCESS Newswire / April 27, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced that its Board of Directors (the "Board") has authorized the repurchase of up to $5.0 million of the Company's common stock. The authorization reflects the Board's confidence in the Company's balance sheet strength, the value of its drug development pipeline and supplement business, and the potential value creation from the recently announced Binding Letter of Intent (LOI) to acquire Dura Driver Control Systems (DCS)."Aspire's strengthened financial position prov

8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)

Company secures Commitment Letter from a leading financial institution of up to $22.5M to finance proposed acquisition of Dura Control Systems (DCS)LOI to acquire DCS, a leading global automotive supplier with $200M+ in 2025 revenue, is not expected to require new equity raise to consummate the purchase ESTERO, FL / ACCESS Newswire / April 20, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company") today announced that it has closed the second and final tranche of the private placement announced on February 11, 2026 (the "Offering") for the purchase and sale of 26,250 shares of Series A Convertible Preferred Stock.Pursuant to the closing of the second and final tranc

Elite Ultra-Marathoner targets her second World Record in two months following historicUltra Jackpot 100 Win ESTERO, FL / ACCESS Newswire / April 17, 2026 / Aspire Biopharma Holdings, Inc.'s (NASDAQ:ASBP) ("Aspire" or the "Company") wholly owned subsidiary, Buzz Bomb Caffeine Company, is proud to announce that elite ultra-marathoner and BUZZ BOMB™ Global Brand Ambassador Ashley Paulson will attempt to shatter the female world record for the fastest 100-mile treadmill run.The historic attempt will take place live at the Boston Marathon Expo at the John B. Hynes Veterans Memorial Convention Center on Saturday, April 18, 2026. This Expo is held in conjunction with the Boston Marathon. Paulson a

8-K/A - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)

8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)

8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)

8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)

ESTERO, FL / ACCESS Newswire / April 16, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced it has entered into a Letter of Intent (LOI) to acquire Dura Driver Control Systems ("DCS"), a premier designer and manufacturer of automotive driver control systems that also apply to other industrial applications. Management of DCS will be bolstered by the addition of a team from Lakewood & Company with more than 100 years' collective experience within the automotive industry.The proposed acquisition represents a transformative milestone for Aspire and position